VINCENT TAM to Retrospective Studies
This is a "connection" page, showing publications VINCENT TAM has written about Retrospective Studies.
Connection Strength
0.418
-
Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
Score: 0.065
-
Correlating Advanced Pharmacy Practice Experience Exam Scores and Pharmacist Licensure Status in a Single Program. Am J Pharm Educ. 2024 Sep; 88(9):101255.
Score: 0.061
-
Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.
Score: 0.035
-
Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8.
Score: 0.033
-
Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.
Score: 0.032
-
Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
Score: 0.032
-
In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6.
Score: 0.030
-
A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102.
Score: 0.025
-
Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4.
Score: 0.022
-
Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008 Oct; 37(10):826-30.
Score: 0.020
-
Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.
Score: 0.016
-
Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003 Mar; 23(3):291-5.
Score: 0.014
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
Score: 0.014
-
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4.
Score: 0.008
-
Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
Score: 0.007
-
Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008 Jul; 62(1):168-71.
Score: 0.005